- Conditions
- Leptomeningeal Metastases
- Interventions
- Deferoxamine (DFO)
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2027
- U.S. locations
- 7
- States / cities
- Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 25–48
of 24
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- AML/MDS, CD33 Expressing Hematological Malignancies, FLT3 Expressing Hematological Malignancies
- Interventions
- SENTI-202
- Biological
- Lead sponsor
- Senti Biosciences
- Industry
- Eligibility
- 18 Years to 74 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2040
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Denver, Colorado • Jacksonville, Florida + 3 more
- Conditions
- Breast Cancer, Glioma, Hepatocellular Cancer, Squamous Cell Lung Cancer, Pancreatic Cancer, Colon Cancer, Prostate Cancer
- Interventions
- Autologous Natural Killer / Natural Killer T Cell Immunotherapy
- Biological
- Lead sponsor
- Envita Medical Center, Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2009
- U.S. locations
- 1
- States / cities
- Scottsdale, Arizona
- Conditions
- Acute Myeloid Leukemia, in Relapse, Acute Myeloid Leukemia Refractory
- Interventions
- CB-012
- Drug
- Lead sponsor
- Caribou Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 10
- States / cities
- Birmingham, Alabama • Denver, Colorado • Tampa, Florida + 6 more
- Conditions
- Salivary Gland Tumor, Urothelial Carcinoma, Ovarian Carcinoma, Breast Cancer, Soft Tissue Sarcoma
- Interventions
- AVA6000
- Drug
- Lead sponsor
- Avacta Life Sciences Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 3
- States / cities
- New York, New York • Houston, Texas • Seattle, Washington
- Conditions
- Acute Myeloid Leukemia, Myelodysplastic Syndromes
- Interventions
- ONC-201
- Drug
- Lead sponsor
- University of Nebraska
- Other
- Eligibility
- 19 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Omaha, Nebraska
- Conditions
- Breast Cancer
- Interventions
- Poziotinib, T-DM1
- Drug
- Lead sponsor
- Spectrum Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years to 90 Years · Female only
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 2
- States / cities
- Anaheim, California • Glendale, California
- Conditions
- Solid Tumor
- Interventions
- LY3415244
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2019
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • New York, New York
- Conditions
- Multiple Myeloma
- Interventions
- Iberdomide, Elotuzumab, Dexamethasone
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2026
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Carcinoma, Midline
- Interventions
- GSK525762
- Drug
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 16 Years and older
- Enrollment
- 196 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 5
- States / cities
- Baltimore, Maryland • Boston, Massachusetts • Philadelphia, Pennsylvania + 2 more
- Conditions
- 11q-deleted Relapsed/Refractory Chronic Lymphocytic Leukaemia (CLL),, Prolymphocytic Leukaemia (PLL), B Cell Lymphomas
- Interventions
- Administration of AZD6738
- Drug
- Lead sponsor
- AstraZeneca
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 2 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Multiple Myeloma, Smoldering Multiple Myeloma, Immunoglobulin Light-chain Amyloidosis
- Interventions
- JNJ-79635322, Daratumumab, Pomalidomide, Lenalidomide
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 276 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 2
- States / cities
- Denver, Colorado • Atlanta, Georgia
- Conditions
- EGFR-Mutant Lung Cancer
- Interventions
- erlotinib
- Drug
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2018
- U.S. locations
- 5
- States / cities
- Basking Ridge, New Jersey • Commack, New York • New York, New York + 2 more
- Conditions
- Malignant Glioma
- Interventions
- Hypofractionated Stereotactic Irradiation (HFSRT), Pembrolizumab, Bevacizumab
- Radiation · Drug
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Advanced Cancer, Metastatic Cancer, Squamous Cell Carcinoma of Head and Neck
- Interventions
- FS118, Paclitaxel
- Drug
- Lead sponsor
- invoX Pharma Limited
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 7
- States / cities
- Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 4 more
- Conditions
- Lymphoma, Refractory Solid Tumors, Advanced Cancer
- Interventions
- ASP4132
- Drug
- Lead sponsor
- Astellas Pharma Global Development, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2018
- U.S. locations
- 5
- States / cities
- New Haven, Connecticut • Chicago, Illinois • Rochester, Minnesota + 2 more
- Conditions
- Metastatic HER2 Positive Gastroesophageal Junction Cancer
- Interventions
- CYNK-101, Pembrolizumab, Trastuzumab, Recombinant Human Interleukin-2, Cyclophosphamide, Fludarabine, Mesna
- Biological · Drug
- Lead sponsor
- Celularity Incorporated
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 3
- States / cities
- La Jolla, California • Washington D.C., District of Columbia • Hackensack, New Jersey
- Conditions
- Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission, Acute Lymphoblastic Leukemia Recurrent, Acute Lymphoblastic Leukemia Not Having Achieved Remission, Acute Lymphoblastic Leukemia, Pediatric, Acute Lymphoblastic Leukemia
- Interventions
- CAR-20/19-T cells (5 x 10^5 CAR-20/19-T cells/kg), CAR-20/19-T cells (1 x10^6 CAR-20/19-T cells/kg), CAR-20/19-T cells (2.5 x10^6 CAR-20/19-T cells/kg), CAR-20/19-T cells
- Biological
- Lead sponsor
- Medical College of Wisconsin
- Other
- Eligibility
- 1 Year to 70 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Milwaukee, Wisconsin
- Conditions
- Prostate Cancer, Metastatic Prostate Cancer, Metastatic Castration-resistant Prostate Cancer
- Interventions
- Carboplatin, 177Lu-PSMA-617
- Drug
- Lead sponsor
- Dana-Farber Cancer Institute
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 37 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 3
- States / cities
- Boston, Massachusetts
- Conditions
- Neoplasm Metastasis, Colorectal Neoplasms, Breast Cancer
- Interventions
- Prexasertib, Cisplatin, Cetuximab, G-CSF, Pemetrexed, Fluorouracil, LY3023414, Leucovorin
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 167 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2020
- U.S. locations
- 5
- States / cities
- Sarasota, Florida • Oklahoma City, Oklahoma • Nashville, Tennessee + 1 more
- Conditions
- Non-Hodgkin Lymphoma, Burkitt's Lymphoma, Chronic Lymphocytic Leukemia, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Lymphoma, Marginal Zone, Waldenstrom Macroglobulinemia, Primary Mediastinal B-cell Lymphoma
- Interventions
- ADCT-402
- Drug
- Lead sponsor
- ADC Therapeutics S.A.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 183 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 8
- States / cities
- La Jolla, California • Atlanta, Georgia • St Louis, Missouri + 4 more
- Conditions
- Hepatocellular Carcinoma
- Interventions
- Valemetostat, Atezolizumab, Bevacizumab
- Drug
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Aggressive Lymphoma
- Interventions
- MS-553, acalabrutinib, venetoclax, Rituximab, obinutuzumab
- Drug
- Lead sponsor
- MingSight Pharmaceuticals, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2023
- U.S. locations
- 5
- States / cities
- Ann Arbor, Michigan • New York, New York • Columbus, Ohio + 2 more
- Conditions
- Advanced Pancreatic Cancer
- Interventions
- AB680, Zimberelimab, Nab-paclitaxel, Gemcitabine
- Drug
- Lead sponsor
- Arcus Biosciences, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 196 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 9
- States / cities
- Santa Monica, California • St Louis, Missouri • New York, New York + 5 more